P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes.

ABSTRACT:

Importance

Physician behavior in response to knowledge of a patient's CYP2C19 clopidogrel metabolizer status is unknown.

Objective

To investigate the association of mandatory reporting of CYP2C19 pharmacogenomic testing, provided to investigators with no direct recommendations on how to use these results, with changes in P2Y12 inhibitor use, particularly clopidogrel, in the Randomized Trial to Compare the Safety of Rivaroxaban vs Aspirin in Addition to Either Clopidogrel or Ticagrelor in Acute Coronary Syndrome (GEMINI-ACS-1) clinical trial.

Design, setting, and participants

The GEMINI-ACS-1 trial compared rivaroxaban, 2.5 mg twice daily, with aspirin, 100 mg daily, plus open-label clopidogrel or ticagrelor (provided), in patients with recent acute coronary syndromes

SUBMITTER: Povsic TJ 

PROVIDER: S-EPMC6547088 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature